Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® for Patients with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
pharmaceutical investing Rhythm Pharmaceuticals Announces Launch of TEMPO Registry for Rare Genetic Disorders of Obesity
pharmaceutical investing Rhythm Pharmaceuticals Receives European Medicines Agency PRIME Designation for Setmelanotide in Rare Genetic Disorders of Obesity
SAGA Metals Announces Additional Assay Results from Drilling at Trapper North, Confirming High-Grade Mineralization at Radar Critical Minerals Project in Labrador
Providence Gold Mines Inc. Announces Final Approval of Reviewable Transaction and The La Dama de Oro Gold Property NI43 101 Report
